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E-mail address: Jean-Marie.PAGES@medecine.univIn Gram-negative bacteria, the envelope is a sophisticated barrier protecting the cell against exter-
nal toxic compounds. Membrane transporters, e.g., porins or efﬂux pumps, are main ﬁlters regulat-
ing the internal accumulation of various hydrophilic molecules.
Regarding bacterial susceptibility towards antibacterial agents, membrane permeability is part of
the early bacterial defense. The bacterium manages the translocation process, inﬂux and efﬂux, to
control the intracellular concentration of various molecules. Antibiotics and biocides are substrates
of these mechanisms and the continuing emergence of multidrug resistant isolates is a growing
worldwide health concern. Different strategies could be proposed to bypass the bacterial membrane
barrier, comprising inﬂux and efﬂux mechanisms, in order to restore the activity of antibiotics
against resistant bacteria.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
After several decades of continued success of antibiotic therapy
against bacterial infections, we are now facing a worrying pros-
pect: the accelerated evolution of antibiotic resistance of
important human pathogens [1–5]. This bacterial adaptation to
antibiotic use is directly involved in the current increase of mor-
bidity and mortality caused by infection diseases. Gram-negative
bacteria that correspond to a prominent part of drug resistant
pathogens, display a complex envelope with an outer (OM) and
an inner (IM) membrane delimiting a periplasmic space [6]. This
cellular organization results in the presence of various protein
channels involved in the transport, uptake or efﬂux, of a large vari-chemical Societies. Published by E
ransporteurs Membranaires,
e, 27 Bd Jean Moulin, 13385
-mrs.fr (J.-M. Pagès).ety of compounds, nutrients or toxic molecules (sugars, drugs,
small peptides, chemicals) (Fig. 1). Among these various channels,
porins and efﬂux transporters contribute to the balance of intracel-
lular drug accumulation and are involved in the bacterial antibiotic
susceptibility [7,8].
Hydrophobic compounds, such as aminoglycosides, macrolides,
rifamycins and other chemicals, can permeate through the OM bi-
layer by the self-promoting pathway [6]. Regarding hydrophilic
molecules, such as b-lactams and ﬂuoroquinolones, the core region
of lipopolysaccharide (LPS) impairs their diffusion and porins are
the major way to enter the cell [6,8]. Consequently, LPS alterations
can provide an efﬁcient protection against the ﬁrst class whereas
porin modiﬁcations can protect bacteria against the second ones.
The permeability of porins to b-lactam antibiotics has been dem-
onstrated by various means and several porin mutants have been
described in resistant clinical isolates [8].
The over-expression of efﬂux pumps is involved in the Multi-
Drug Resistance (MDR) phenotype associated with other morelsevier B.V. All rights reserved.
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Fig. 1. Steps of antibiotic transport through the membranes of Gram-negative bacteria. To be active against bacterium, an antibiotic needs a critical concentration threshold
to inhibit the corresponding target. Using the concentration gradient, the inﬂux is controlled by several elements: the antibiotic can permeate through the OM via porins (a,
for hydrophilic molecules) or through the OM (b, for hydrophobic drugs) [6]. (c) Represents the diffusion through the periplasmic space in which enzymatic inactivation may
occur [26,27]. Finally, the drug will pass the cytoplasmic/IM (d). Regarding the efﬂux, the drug may be recognized and transported by active pump (e) or (f). The pump (e.g.,
AcrB) has to recruit the OM pore TolC (g), in addition it may conjointly acts with other pumps (e.g., MFS family). The success of a drug is given by the kinetics of all individual
steps [12,110].
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enzymatic modiﬁcation of the antibiotic [9,10]. In addition to ef-
ﬂux pump over-expression, a severe down regulation of porin syn-
thesis have been reported in various enterobacterial resistant
isolates including Escherichia coli, Enterobacter aerogenes, Klebsiella
pneumoniae, etc [8]. In these strains, a complex regulation cascade
is involved in the control of membrane transporters, porins and ef-
ﬂux pumps.
This regulation cascade involved the mar and ram genes that
organize a tight and coordinated control of the expression of porins
and efﬂux pumps in E. aerogenes, K. pneumoniae and Salmonella
enteritidis [10]. Various chemicals, antibiotics, biocides, and other
molecules can trigger this regulation cascade [9,10]. The main clin-
ical concern of efﬂux pump expression is related to their broad
polyselectivity and their ability to expel a large collection of mole-
cules [11–14]. In Gram-negative bacteria, the archetype of drug
efﬂux pump is the AcrAB-TolC/MexAB-OprM [15–20]. Firstly
characterized in E. coli and Pseudomonas aeruginosa (Fig. 1), Ac-
rAB-TolC/MexAB-OprM efﬂux pump is the main multitransporter
system reported in enterobacterial clinical isolates [7,11–14]. Ac-
rAB-TolC homologous efﬂux complexes have also been reported
in many other pathogens [11–14]. The poly-speciﬁcity of trans-
porters confers a ‘‘general resistance mechanism’’ contributing to
the ﬁrst line of bacterial defense that can favor the acquisition of
other resistance mechanisms such as target mutations or drug
modiﬁcations [10,11]. It has been demonstrated that the expres-
sion of Salmonella and Campylobacter efﬂux pump is an important
prerequisite for the selection of ﬂuoroquinolone resistant strains
exhibiting target mutations [10,21]. The mechanics of efﬂux pump
have been investigated and dynamic-functional models have been
recently proposed [12,20,22–24]. In addition, recent data indicate
that some drug transporters, e.g., MdfA and AcrAB-TolC, can coop-
erate or can act sequentially to efﬁciently expel antibiotics outside
the bacterium [25].
These two transport mechanisms, inﬂux (porin and self-
promoting pathway through LPS) and efﬂux (efﬂux pumps), that
canbegenetically regulatedbya samegenetic cascade involvingglo-
bal regulators and speciﬁc local regulators, can cooperate to strongly
decrease the intracellular concentration of antibacterial agents.These processes conjointly contribute to the membrane barrier, or
mechanical barrier, that constitutes the ﬁrst line of bacterial defense
against antibacterial agents comprising antibiotics, biocides
(disinfectants, antiseptics, preservatives), bacteriocins, detergents,
surfactants, defensins, bile salts and also dyes and other chemicals.
Consequently, in order to bypass the membrane barrier existing
in resistant isolates, we need to develop various strategies to in-
crease the diffusion of antibiotics through bacterial membranes
(target the inﬂux), or/and, circumvent the pump mechanism to
preserve a high intracellular concentration of antibiotics (target
the efﬂux).
2. Increasing the antibiotic inﬂux
During last decade, in order to restore the efﬁcacy of b-lactams
or other antibiotics in multidrug resistant strains, several ways
have been investigated. In addition to explore new compounds
able to inhibit cephalosporinase and other enzymatic activities
[26,28], an alternate possibility is to facilitate the diffusion of anti-
biotics through the bacterial envelope in order to increase their
intracellular concentration (see Fig. 1, arrows a and b). To bypass
the barrier due to porin alterations (decreased expression or al-
tered channel) and LPS modiﬁcations, chemical facilitators and
chemosensitizers, have been proposed such as detergents, surfac-
tants, chaotropic agents, polymyxines, antimicrobial peptides
[29,30]. Some of them, e.g., polycationic cyclic lipopeptides and
cationic antimicrobial peptides have been assayed in combination
with usual antibiotics to combat resistant clinical strains [for re-
cent reviews see 31–33]. It is important to note that only very
few results have been published regarding the molecular basis of
this kind of combination, the synergy efﬁcacy, the concentration
ratio, the kinetics, and the combination parameters.
2.1. Polymyxins as chemosensitizers
Membranotropic compounds such as polymyxin B and poly-
myxin E (colistin) perturb the integrity of the bacterial membranes
and can increase the enterobacterial susceptibility to various com-
pounds [33]. In addition, they can act as opsonins to enhance
1684 J.-M. Bolla et al. / FEBS Letters 585 (2011) 1682–1690destruction by phagocytic cells. These molecules are pentacationic
cyclic lipodecapeptides that present bactericidal activity by acting
on the outer membrane of Gram-negative bacteria [33,34]. Their
action is limited to Gram-negative bacteria and polymyxin used
was almost halted between 1970 and 1980 as systemic therapy
due to their severe nephrotoxicity. The molecular mechanism for
permeabilization by polymyxin B is thought to involve the compe-
tition for the binding of divalent cations that normally cross-bridge
neighboring LPS molecules. The displacement of these stabilizing
interactions leads to enhance lateral diffusion of LPS [33,35]. The
resulting destabilization of the LPS layer allows the penetration
of polymyxin B into the periplasm, providing essentially a ‘‘self-
promoted uptake pathway’’ for polymyxin B to reach its target,
the cytoplasmic membrane. Then, the fatty acid tail on polymyxin
B allows it to permeabilize the IM, thus leading to its antibacterial
action. Polymyxin B nonapeptide (PMBN) lacks the fatty acid chain,
and is less bactericidal and less toxic for eukaryotic cells, but the
fact that it sensitizes cells to hydrophobic antibiotics demonstrates
that it retains membrane permeabilizing properties [33].
Now, faced with the continuous increase of infectious diseases
involving MDR bacteria and with the scarcity of new active antibi-
otics, polymyxin group represents a last resort for clinicians
[33,36,37]. Regarding their use in monotherapy, it must be noted
that polymyxin resistance has been reported for clinical isolates
although the resistant strains showed a noticeable decrease of ﬁt-
ness [33,38]. A possible alternate way is to combine low concentra-
tion (sub-inhibitory) of polymyxin with another clinical antibiotic
to synergize its activity. Interesting results have been reported and
the combination of meropenem and colistin showed increased syn-
ergic killing of Acinetobacter baumannii and P. aeruginosa [39]. Sim-
ilar results have been reported with a combination of high-dose
tigecycline and colistin [40]. A synergistic combination of colistin
with rifampin [41] and vancomycin [42] has been reported.
Moreover, signiﬁcant bactericidal activity was obtained in carba-
penem-resistant K. pneumoniae, A. baumannii, P. aeruginosa, and
E. coli isolates using combinations of polymyxin B, doripenem,
and rifampin [43]. Combination of polymyxins with these antibac-
terials may support a strategy for treatment of patients infected
with such bacteria exhibiting resistant phenotype. The effect and
kinetics reported may suggest that polymyxin may favor the entry
of b-lactam molecules or other antibiotics. Polymyxin B and
colistin have been also successfully used in combination with tige-
cycline and gentamicin against Gram-negative resistant isolates
[44]. Consequently they are mentioned on the treatment of resis-
tant bacterial infections and with association with particular anti-
biotics [33]. Interestingly, it has been recently demonstrated that
PMBN and polymyxin B can potentialize the activity of a new fam-
ily of antibacterial agents, peptide deformylase inhibitor, against
Gram-negative bacteria such as E. coli, E. aerogenes, K. pneumoniae,
and P. aeruginosa [45]. The increase of bacterial susceptibility is
associated with the increase of the entry of new antibacterial
agents obtained by the addition of sub-inhibitory concentration
of polymyxin [45].
Less toxic polymyxin derivatives would be highly welcome,
such as the polymyxin B non-apeptide, to be used in combination
with usual antibiotics [33]. Interestingly, the group of M. Vaara has
produced and characterized many polymyxin derivatives showing
a signiﬁcant decrease in toxicity but exhibiting chemosensitizer
properties. Using sub-inhibitory concentrations, some compounds
are able to increase the activity of rifampin, clarithromycin, vanco-
mycin to E. coli, K. pneumoniae, Klebsiella oxytoca, Enterobacter
cloacae, Citrobacter freundii, and A. baumannii [33,46]. In addition,
a compound is effective in combination with erythromycin in an
infection animal model [33]. Furthermore, it is important to men-
tion that the use of polymyxin compounds in combination with an-
other antibiotic may reduce the risk of resistance emergence [33].Interestingly, some natural compounds can act as membrane
permeabilizers. The terpenic compound, eugenol is the major com-
ponent of clove oil from Eugenia aromatica and was reported to act
primarily by disrupting the cytoplasmic membrane [47]. The com-
bination study of eugenol and ten antibiotics against Gram-
negative bacteria, E. coli, P. aeruginosa, E. aerogenes, Salmonella
typhimurium and Proteus vulgaris indicated that the minimal inhib-
itory concentration (MIC) of the antibiotics was 5–1000-fold lower
than when used alone, indicating that the combination was syner-
gistic [48]. The enhancement of nitroceﬁn uptake associated with a
sensitization of the microorganisms to lysis by lysozymes or deter-
gents in the presence of eugenol demonstrated its effect on the
bacterial membrane.
2.2. Destabilization of LPS barrier
An other way to circumvent the membrane barrier is to desta-
bilize the LPS layer by using chaotropic agents or detergents that
consequently facilitate the diffusion of hydrophilic compounds
through the membrane lipid bilayer. Treatment by Tris/EDTA leads
to massive release of LPS in the medium, and it is believed that the
reduced amount of LPS in the OM leaﬂet is compensated by glycer-
ophospholipids, essentially creating patches of phospholipid bi-
layer, which are much more permeable to lipophilic compounds
[6]. A similar situation may also be found in deep rough mutants
where there is a decrease in OM protein incorporation associated
with the expression of defective LPS molecules generating an
unbalanced ratio of LPS/phospholipids/proteins in the OM. The
achieved susceptibilities become similar to those of deep rough
mutants [6]. It has been demonstrated that LPS mutants are more
susceptible to antibiotics. However, a major adverse effect in the
use of chaotropic agent (EDTA) is associated with their noticeable
toxicity on biological membrane and consequently, their use is
limited to laboratory assays.
For laboratory assays including diagnostic assays, evaluation of
resistance, detection of involved mechanisms and epidemiology
surveys, several compounds have been used in combination with
antibiotics. EDTA could be used to promote the entry of various
antibiotics in resistant strains exhibiting some LPS alterations or
to reduce the enzymatic activity against speciﬁc antibiotics
[6,49]. EDTA can increase the susceptibility of bacteria producing
metallo-b-lactamases towards b-lactams [27]. Some detergents,
like Triton or SDS, deoxycholate, could be used to permeabilize
the OM and in addition facilitate the entry of various antibacterial
agents and subsequently increase the susceptibility [6]. Regarding
the use of detergents or biocides in combination with antibiotics,
the situation is especially complex and depends on the speciﬁc
use (skin treatment, local decontamination, medical devices or
catheters treatment).
Ceragenins are a family of bile acid derivatives that have been
modiﬁed to yield an amphiphilic morphology similar to that of
endogenous antimicrobial peptides [50]. With relatively low con-
centrations of ceragenin, a permeabilization of the OM was ob-
served and a synergistic effect of ceragenin and erythromycin in
combination was also observed [51]. In addition, a synergistic ef-
fect is observed with combination of ceragenins and host defense
molecules on resistant P. aeruginosa isolates [52]. Recently, squal-
amine, a natural aminosterol, has been studied for its antimicrobial
activity and this molecule is able to destabilize the OM of various
Gram-negative bacteria [53,54]. In combination with usual antibi-
otics, squalamine can restore susceptibility to various antibiotic
classes including b-lactams, ﬂuoroquinolones, macrolides, pheni-
cols, cyclines to resistant isolates that are devoid of porins [55].
This is interesting in the case of cefepime or ciproﬂoxacin, two
antibiotics that required porins to penetrate the OM [6,8]. Neamine
derivatives represent also a possibility to permeabilize bacterial
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strated that some neamine compounds are able to induced a de-
crease of the thickness of P. aeruginosa envelope in parallel with
membrane depolarization. In addition, a binding to LPS and the
induction of membrane permeabilisation is reported with some
speciﬁc neamine derivatives [56].
In conclusion, these data suggest than this class of amphiphilic
derivatives could be used for the development of a direct antibacte-
rial agent, or alternatively for the production of original adjuvants
that rejuvenate old antibiotic activity on MDR bacteria [57,58].
2.3. Nanoparticles and antibiotics
At this moment, new complexes using nanoparticle technology
have been produced and comprise several antibacterial agents
associated with nanoparticle surfaces. This new presentation of
antibacterials is attractive for efﬁciently combating resistance
associated with bioﬁlm structures or bacterial isolates exhibiting
a modiﬁed envelope that contributes to antibiotic resistance.
Now, precise informations are needed to clearly identify the bene-
ﬁt and possible use of such approach. A serious concern associated
with biomedical and surgical devices and transplants, grafts, and
other invasive treatments, is that of bacterial infections and the de-
vices colonized by bacteria may cause infection or mortality. To
prevent and to combat such infections, an effective strategy is to
develop original surface modiﬁcation processes that provide anti-
bacterial abilities to biomedical devices [59].
Nano silver particles comprise nano-sized structures formed
from silver atoms. It is proposed that silver ions interact with main
bacterial components to produce the bactericidal effect: the pepti-
doglycan and the membrane, DNA and proteins and especially en-
zymes involved in vital cellular processes such as the electron
transport chain [for a review see 60]. Taking into account these
destabilizing effects generated in the bacterial envelope, it may
be possible to propose a combination of such new medical devices
associated with usual antibiotics for the treatment of speciﬁc infec-
tious diseases caused by resistant bacteria [61,62].
3. Blocking the efﬂux
Because of the clear involvement of the resistance nodulation
cell division (RND) transporters in the increased frequency of
MDR clinical bacteria, efﬂux pumps are now considered as an
attractive target for the development of a combinational therapy
using antibiotic/efﬂux pump inhibitor (EPI) as adjuvant of usual
antibiotics [28]. The deciphering of structure and function, e.g.,
structure–activity relationship (SAR) of the RND efﬂux pump and
its individual components is required for their rational design
[28,63]. All details of interactions and processes that functionally
govern and regulate the behaviour of the RND family can be useful
for the development of an effective new mode of therapy. The de-
sign of active molecules capable of restoring antibiotic susceptibil-
ity in MDR pathogens is a promising alternative taking into
account the scarcity of new molecules available and active against
Gram-negative bacteria. These compounds must have no intrinsic
antibacterial effect but induce an increase of intracellular antibiotic
concentration. Some data provide some clues for the future devel-
opment of distinct strategies targeting efﬂux pumps: alteration of
pump gene expression, inhibition of membrane assembly of pump
component, blocking OM exit duct, collapsing the energy driven
source [21,63–65]. At the moment, efﬂux pump activity blockers
are the main group that are described and tested on Gram-negative
bacteria from both, natural and synthetic sources.
Although several families of chemical compounds that display
EPIs activity have been identiﬁed, the EPIs-library is still not sufﬁ-
cient for a complete characterization of various aspects of multi-drug resistance in Gram-negative bacteria. Many lines of
evidence indicate that in case of tripartite pumps, AcrAB-TolC or
MexAB-OprM, the RND protein (AcrB or MexB) is responsible for
selection of a substrate to be extruded. Thus, lot of efforts are con-
centrated on search for compounds which tend to afﬁne to these
RND-proteins and, in this way, they could inhibit their efﬂux ac-
tion. The 3D-structure of AcrB has been identiﬁed experimentally
in several variants [66–69] for last eight years. Twenty ﬁve struc-
tures of AcrB have been submitted in Protein Data Bank (PDB) since
2002. In case of MexB, the ﬁrst experimental structure has been
available in PDB since 2009 [70]. It gives a great perspective to de-
velop knowledge about the efﬂux mechanism and substrates bind-
ing pockets to discover new groups of efﬂux pump inhibitors.
Nevertheless, a number of described potent EPIs is rather low, par-
ticularly, the number of inhibitors that were found basing on dock-
ing studies to the binding sites identiﬁed for the tripartite pumps
within both mutagenic- and computer aided modelling studies. A
natural non-selective character of the bacterial efﬂux proteins
enables pathogens to abroad substrates with wide varieties of
spatial and physicochemical properties [71]. Structure–activity
relationship studies performed for families of known EPIs (Table 1),
gave ‘‘step by step’’ new information about electron- and spatial
properties of inhibitors that could be used to create pharmaco-
phore models describing features likely necessary to interact with
protein pump binding sites. The pharmacophore models could be
useful for design of novel compounds with expected higher EPI-
properties. Molecular modelling based pharmacophore model of
Nakayama et al. [72] allowed to identify favourable features for
inhibitors of MexAB-OprM in P. aeruginosa in the group of pyrido-
pyrimidine derivatives. According to this model, four hydrophobic
sites, including two sites in close neighbourhood and two periphe-
ral sites, as well as an acidic ionisable fragment are desirable for
EPI properties. The model of Nakayama allowed ﬁnding new active
EPIs among pyridopyrimidine derivatives. Nevertheless, other
active EPIs (Table 1) do not ﬁt in the model as their number and
position of hydrophobic sites are different, and acidic ionisable
centre appears rather occasionally. A structure–activity relation-
ship analysis which can be performed across all families of
described EPIs (Table 1) gives information about structural require-
ments that may be desirable for interactions with efﬂux system of
Gram-negative bacteria. The presence of various linear- or cyclic
amines as well as aromatic moieties, often in neighbourhood
(fused aromatic rings of naphthyl or quinoline side chains), can
be noted in all representative EPIs. Amide fragments appear in sev-
eral groups of EPIs, in which hydrogen bond acceptor on carbonyl
oxygen may interact with amino acid residues of a binding pocket
of protein pumps. Among the synthetic products with anti-efﬂux
properties, the following chemical families stand out.
3.1. Synthetic products as efﬂux pump activity blockers
3.1.1. Peptidomimetics
In the case of synthetic compounds, the ﬁrst recognized EPIs be-
long to peptidomimetic group [73], which are active against
P. aeruginosa strains that overexpress the MexAB-OprM efﬂux
pump. These compounds are the ﬁrst described molecules that
are able to block ﬂuoroquinolone efﬂux using levoﬂoxacin as
marker [74]. Phe-Arg-b-naphthylamide (PAbN) was the ﬁrst EPI-
peptidomimetic, selected as a pioneer lead compound for further
chemical modiﬁcations. PAbN-like peptidomimetics effectively in-
hibit the quinolone efﬂux mechanism in P. aeruginosa strain
expressing MexAB-OprM, particularly levoﬂoxacin efﬂux. This
group of EPIs induces a competition-like process during the recog-
nition/transport steps of antibiotic molecule [21,63]. EPI activity of
PAbN was also conﬁrmed in other Gram-negative bacteria, includ-
ing E. coli, E. aerogenes, K. pneumoniae and S. enterica [21,63,75].
Table 1
Most active efﬂux pump blockers, with antibiotics and bacterial species in which their activity has been demonstrated.
Compound Molecular structure Bacterial species Antibiotic Reference
Synthetic products Peptidomimetics
N
H
N
O
N
H
O
H
N
H2N MC-04,124
N
H
O
N
H
NH
NH2
H
N
O
H2N
PAβN
P. aeruginosa, E. coli, E.
aerogenes, K.
pneumoniae, S. enterica
Quinolones [63,73–
80]
Quinolines/
quinazolines
O2N N
HN
N
N
N
HN N
O
BG 814
BG 1167
E. aerogenes Quinolones
Phenicols
Cyclines
Ethidium bromide
[21,63,81–
83]
Arylpiperazines
N
NH
NMP
E. coli, Acinetobacter
baumanii
Fluoroquinolones [85–90]
Phenothiazines
S
N
N
Cl
Chlorpromazine
S
N S
N
Thioridazine
B. pseudomallei, S.
enterica, M. avium, M.
smegmatis, E. coli
Ethidium bromide
Aminoglycosides, Levoﬂoxacin
[95–99]
Natural products Lupulone,
Humulone ,
Xanthohumol
OH O
OHO
Lupulone
OH O
OHO
OH
Humulone
HO
OH O
O
OHXanthohumol
P. mirabilis, S.
marcescens, P. vulgaris
Polymyxin B [108]
Eugenol
O
OH
E. coli, P. aeruginosa, E.
aerogenes, S.
typhimurium, P. vulgaris
b-Lactams, Erythromycin, Norﬂoxacin,
Chloramphenicol, Polymyxin B,
Tetracycline, Vancomycin, Rifampycin
[48]
Geraniol
HO
E. aerogenes, E. coli, P.
aeruginosa, A. baumanii
Chloramphenicol, Norﬂoxacin [109]
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with antibiotic substrates of the efﬂux pump system; that is while
the pump preferentially pumps out PAbN, the antibiotic remains in
the cell increasing its amount until the concentration required for
its activity on the target is sufﬁcient. The ﬁnal effect of PAbN is to
reduce resistance or completely reverse resistance to a given anti-
biotic to which the bacterium was initially resistant. Results of var-
ious microbiological assays suggested that PAbN may occupy an
afﬁnity site in the large substrate-binding pocket which differs
from the site occupied by a given antibiotic in respect to the in-
volved amino acid residues [76].
Derivatives molecules from PAbN-EPIs have been prepared in
order to improve the stability in biological ﬂuids, the activity and
the pharmacokinetic properties of the EPI [71]. One of them, MC-
04,124, is more stable than the original molecule and exhibits
reduced toxicity [77,78]. These EPIs are useful to identify the pres-
ence of active efﬂux pump in P. aeruginosa clinical isolates [79].From this original family of diamine EPIs several compounds have
been described [80]. At this moment, these PAbN-derived EPIs are
the more studied and developed family of anti-efﬂux compounds.
One of them is under early phase preclinical development by
Mpex Pharmaceuticals. This company is now developing a ﬁxed-
combination drug product consisting of an existing antibiotic and
an EPI for systemic treatment of serious hospital-acquired infec-
tions due to MDR Gram-negative bacterial pathogens such as
P. aeruginosa.
3.1.2. From quinoline to quinazoline derivatives as AcrB blockers
A screening test bases on clinical isolates of E. aerogenes has al-
lowed the identiﬁcation of quinoline, quinazoline derivatives, two
new classes of efﬂux pump blockers [81–83]. The compound struc-
tures have been selected according to their structural similarity
with quinolones, a main efﬂux substrate. The activity of these com-
pounds has been evaluated on a collection of MDR clinical strains
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including efﬂux pumps, altered membrane organisation, target
mutations and enzymatic barriers [10]. In each class, some deriva-
tives (Table 1) noticeably increase the susceptibility to the quino-
lone, phenicol and cycline antibiotics, all of which being
substrates of efﬂux pumps of E. aerogenes [21,63,81–83]. In addi-
tion, they also increased the intracellular accumulation of radiola-
belled norﬂoxacin or chloramphenicol [81–83]. The difference in
the restoration level obtained with the various derivatives and
the antibiotics tested may reﬂect: (i) a variation in the respective
location of ligands inside the AcrB cavity such that binding of a
compound interferes with the extrusion of the antibiotic; (ii) a
competition between the antibiotic and derivative for the same
pump active site; (iii) the compounds differ with respect to the de-
gree of afﬁnity for a speciﬁc internal site; and (iv) binding of the
compound reduces the afﬁnity of the antibiotic to a different site.
The presence of different sites located inside the AcrB pump has
been reported [12,69]. With the recent model illustrating function-
ing of the AcrB pump [16,19], it is possible that the same amino
acid residues participated at different drug binding sites located
in the pump tunnel. Moreover, several recent data on the E. coli
AcrB efﬂux mechanism indicate that some amino acid residues
are involved in the transport process to a varying extent during
speciﬁc steps such as recognition, binding, transport and release
[7,12,69,84]. This can explain the divergence observed in the com-
petitive capacity of the compounds with drugs of different families
(chloramphenicol, quinolones, ethidium bromide) for binding sites
within the pump type (AcrB, MexB) as well as the level of ex-
pressed efﬂux pump activity in the tested strains [12,63]. Analyses
of structure–activity relationships regarding homologous deriva-
tives allowed the identiﬁcation of pharmacophoric proﬁle in each
class of compounds.
3.1.3. Arylpiperazines
The screening of a limited library indicated that several arylpip-
erazines are able to block RND-type efﬂux pumps in E. coli [85]. The
blocking activities of these compounds are modulated by the
spacer length between the benzene ring and the piperazine ring
as well as halogenic substitutions at the benzene ring. Among
piperazine compounds, NMP (Table 1) was the most active unsub-
stituted arylpiperazines that increases the intracellular concentra-
tion of diverse substrates such as ﬂuoroquinolones and ﬂuorescent
dyes [86,87]. NMP was active in several bacterial species including
A. baumannii, in different Enterobacteriaceae, but less efﬁcient in P.
aeruginosa [86–90]. The mechanism of action of NMP and related
compounds has not been elucidated and because of the primary
activity (‘‘serotonin agonist’’ properties), they are likely to be too
toxic for clinical use. Nevertheless, arylpiperazine could be an
interesting pharmacophoric group for other molecular structures
as hydantoins [91–94] which are promising agents to combat bac-
terial resistance (Handzlik et al., unpublished data).
3.1.4. Phenothiazines
Phenothiazines are an other class of EPIs, or indirect effectors of
antibiotic potency; derivatives such as chlorpromazine or thiorid-
azine, have been proved to sensitize resistant bacteria to the anti-
biotic to which it was initially resistant [95].
For example the activity of antimicrobials against Burkholderia
pseudomallei and Salmonella enterica has been increased using phe-
nothiazines [96]. Moreover, in the presence of chlorpromazine, the
efﬂux of ethidium bromide was decreased in the wild type parental
strain as well as with thioridazine, those activity was recognized in
Mycobacterium avium and smegmatis [97].
Because the primary mode of action of phenothiazines is to in-
hibit enzyme activities involved in the generation of metabolic
energy the question of whether a similar mechanism was involvedin the EPI activity of this group of agents, was of importance [98].
The effect of phenothiazine on efﬂux activity was demonstrated by
measuring the accumulation and extrusion of ethidium bromide
[99].
The activity of phenothiazines on the strain over-expressing
efﬂux pump AcrAB E. coli has been reproduced with other Gram-
negative bacteria [99]. From these preliminary data, the study on
phenothiazines will be attractive for developing new physiologi-
cally relevant EPIs [63].
3.2. Natural products as a source of bacterial resistance modulators
Plants have exceptional ability to produce cytotoxic agents, and
there is an ecological rationale that antimicrobial natural products
should be present or synthesized de novo in plants followingmicro-
bial attack to protect themselves from pathogenic microbes [100].
The scarcity of infective diseases in wild plants is in itself an indica-
tion of the successful defense mechanisms developed by them.
Numerous data are already available on Gram-positive resis-
tance modulators in crude plant extracts or isolated from natural
products [101] with the lead example of the 50-methoxyhydnocar-
pin produced by berberry plants that inhibits efﬂux of staphylococ-
cals [102] thus allowing the active hydrophobic alkaloid berberine
to reach its target [103]. In Gram-negative bacteria, despite the lim-
ited results available, some very interesting tracks are open [100].
Ethanol extract from Mentha avensis, an herbaceous plant that
occurs in the whole of South America, was shown to strongly de-
crease resistance to gentamicin of an E. coli clinical isolate [104].
The same authors reported that extracts from Turnera ulmifolia
could be used to increase the susceptibility of E. coli to aminogly-
cosides probably by altering efﬂux pump activity [105]. However,
in both cases the active compound was not identiﬁed from the
extracts.
Lemongrass oil (Cymbopogon citratus) or its main component,
citral, were tested alone or in combination with streptomycin
and kanamycin on Salmonella species. A synergy was observed
for one strain of S. typhimurium in each combination between nat-
ural products and kanamycin or streptomycin. The stronger effect
was observed with the combination of the essential oil and kana-
mycin [106]. Interestingly, citral derivatives have been showed to
efﬁciently block NorA pump [107].
Three molecules isolated from the hop ﬂower, lupulone (also
known as beta-acid), humulone and xanthohumol were tested in
combination with antibiotics on various Gram-negative bacteria.
The disc diffusion assay was used to measure susceptibility to
polymyxin B and zones of inhibition were compared from regular
plates, to plates containing molecules at a sub-inhibitory concen-
tration. Results indicated that in the presence of lupulone, inhibi-
tion zones around the polymyxin B discs increased for Proteus
mirabilis, Serratia marcescens and P. vulgaris; the latter showing
the most signiﬁcant response, the inhibition zone increasing from
0.05 cm to 0.8 cm in the presence of the product [108]. Authors
hypothesized that the changes in envelope permeability, which
may favor the penetration or reduce the efﬂux, caused by the
hop compounds help in overcoming the resistance associated with
bacterial membrane.
The essential oil of the Corsican Helichrysum italicum (HI) exhib-
ited a strong activity against MDR E. aerogenes clinical isolates.
Moreover, the essential oil was also efﬁcient in modulation of bac-
terial resistance of E. coli, P. aeruginosa and A. baumanii strains. Ef-
ﬂux pump mutants analysis showed that HI could modulate the
AcrAB efﬂux mechanism and other resistance mechanisms that
are produced in MDR Gram-negative bacteria. Composition deter-
mination of HI indicated that the activity described comes at least
in part from geraniol, which was not described to date as modula-
tor of antibiotic resistance [109].
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Decrease of membrane permeability associated with over-
expression of efﬂux pumps largely contribute to the MDR phe-
notype. Down regulation of porins synthesis is described in a
large collection of resistant clinical isolates associated or not
with an alteration of OM organization e.g., modiﬁcation of LPS
structure.
It is now admitted that the membrane-associated mechanisms
of resistance represent a key step for clinical isolates and it is
urgent to deﬁne new ways to circumvent these bacterial mecha-
nisms. The re-use of polymyxins reported by several teams
illustrates a possible strategy to combat MDR bacteria. With our
increasing knowledge of antibiotic translocation through bacterial
membrane, e.g., inﬂux and efﬂux processes, in clinical isolates and
the molecular details of transporter–ligand interactions, we can
consider new possibilities in order to restore intracellular antibi-
otic concentrations. Attempts to develop original agents to combat
this membrane barrier mechanism used by bacteria include the re-
search and development of inhibitors of multidrug efﬂux pumps
and of entry facilitators.
The variety and redundancy of membrane transporters involved
in the efﬂux pump activity, the bacterial membrane organization
and toxicity issues have hampered this. However, the recent stud-
ies focused on the speciﬁcity and mechanics (structure–activity
relationships) of drug efﬂux may lead to the development of per-
haps more effective inhibitors that exhibit a reduced toxicity asso-
ciated to an efﬁcacy in restoring the antibiotic accumulation inside
the bacterium. These new agents may be able to rejuvenate the
activity of ‘‘old antibiotics’’ against MDR bacteria. A functional,
pharmaco-chemical and structural analysis of pump–substrate
interactions will be engaged to decipher the molecular bases of
interaction of the pump with speciﬁc ligands allowing us to devel-
op the rational synthesis of efﬂux inhibitors.
Regarding molecules able to facilitate the entry of antibiotics,
several main aspects must be considered, toxicity on membrane
and adverse side effects on eukaryotic cells, two-step entry in
Gram-negative bacteria, OM and IM, for antibiotics that must reach
a cytoplasmic target (proteins, nucleic acids). The natural com-
pounds, polycationic cyclic lipopeptides and cationic antimicrobial
peptides and the new derivatives issued from polymyxin class are
quite attractive but required intensive studies to determine activ-
ity, stability and toxicity. A major issue must address the pharma-
cokinetic and pharmacodynamic aspects of these membranotropic
molecules as a therapeutic agent and their precise conditions of
use.
Until now, most adjuvants or chemosensitzers have been iden-
tiﬁed through usual random screening of synthetic compounds or
natural-product libraries. With the improved resolution of the 3D
structures of membrane components and bacterial transporters,
the dynamic simulations and molecular modelling (SAR, QSAR,
HQSAR), and the recent approaches about the kinetics of transport
(inﬂux and efﬂux), it will be possible to design the pharmacophoric
groups involved in the drug translocation. However, this original
way requires studies about the penetration and membrane diffu-
sion and also toxicity of such complex compounds.
Whatever the selected ways, favoring the entry or blocking the
efﬂux, a functional pharmaco-chemical and biological-structural
analysis of adjuvant-antibiotic interactions must be engaged to
determine the best efﬁcient combination in order to combat spe-
ciﬁc MDR bacteria and prevent the emergence of new resistances
against the adjuvant action.
Regarding the future of these adjuvants in combination with
antibiotics, the development and current use of b-lactamase inhib-
itors such as clavulanate or tazobactam is an encouraging and
fruitful clinical example.Acknowledgements
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